Quang Nguyen Thanh, Jang Jichan
Molecular Mechanisms of Antibiotics, Division of Life Science, Department of Bio and Medical Big Data (BK21 Four Program), Research Institute of Life Science, Gyeongsang National University, Jinju, South Korea.
Front Pharmacol. 2021 Aug 30;12:724725. doi: 10.3389/fphar.2021.724725. eCollection 2021.
has been recognised as a dreadful respiratory pathogen among the non-tuberculous mycobacteria (NTM) because of misdiagnosis, prolonged therapy with poor treatment outcomes and a high cost. This pathogen also shows extremely high antimicrobial resistance against current antibiotics, including the anti-tuberculosis agents. Therefore, current chemotherapies require a long curative period and the clinical outcomes are not satisfactory. Thus, there is an urgent need for discovering and developing novel, more effective anti- drugs. In this review, we sum the effectiveness of the current anti- drugs and drug candidates. Furthermore, we describe the shortcomings and difficulties associated with drug discovery and development.
由于误诊、治疗时间延长、治疗效果不佳以及成本高昂，它已被公认为非结核分枝杆菌（NTM）中一种可怕的呼吸道病原体。这种病原体对包括抗结核药物在内的现有抗生素也表现出极高的耐药性。因此，目前的化疗需要较长的治愈期，临床效果并不令人满意。因此，迫切需要发现和开发新型、更有效的抗药物。在这篇综述中，我们总结了现有抗药物和候选药物的有效性。此外，我们还描述了药物发现和开发中存在的缺点和困难。
